Skip to main content
Sweden
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
  • Aidian – Your aid in diagnostics
  • Produkter
  • Om oss
  • Nyheter
  • Instrument service
  • Antimikrobiell resistens
  • Aidian Academy
  • Mässor & utställningar
  • Våra kunder berättar
Kontakt Sök
Logo
Kontakt
  • Patientnära diagnostik
  • Mikrobiologi
  • Molekylär mikrobiologi
  • Hygienkontroll
  • RIA / Kollagener
  • Luftvägsinfektioner
  • Andra
Patientnära diagnostik
  • QuikRead go-systemet
  • QuikRead 101
  • Nova Biomedical
  • SD BIOSENSOR STANDARD F
  • bioLytical Laboratories INSTI®
  • ACRO™ Biotech
  • microINR
  • Certest
  • Actim
  • Hangzhou AllTest Biotech
Läs mer
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go CRP
  • QuikRead go CRP+Hb
  • QuikRead go wrCRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go tillbehör
QuikRead go
Mikrobiologi
  • Uricult
  • Uricult Vet
  • Cultura M
  • Reagena
  • MIKROGEN serologi
  • Meridian Immunoassays
  • Meridian Curian®
Läs mer
Molekylär mikrobiologi
  • Meridian Revogene®
  • Meridian Alethia®
  • MIKROGEN molecular diagnostics
  • SD BIOSENSOR STANDARD M10
Läs mer
Hygienkontroll
  • Easicult
  • Hygicult
  • Clean Card PRO
Läs mer
RIA / Kollagener
  • UniQ RIA
Läs mer
Andra
  • Grifols Promonitor®
Läs mer
  • Aidian i Sverige
  • Styrelse och ledning
  • Hållbarhet
  • Kultur
  • Karriär hos Aidian
  • Nyheter
  • Produktnyheter
  • AMR
  • Möten
  • Stories from customers
  • COVID-19
  • QuikRead go -serviceorder
  • Vanliga frågor och svar
  • Kontaktinformation
  • Om C-reaktivt protein (CRP)
  • CRP och nedre luftvägsinfektioner
  • Material
  • QuikRead go CRP-produkter
  • Spridning av antibiotikaresistenta bakterier
  • Användbara länkar
  • Allmänt
  • Produktinformation
  • Kurser
  • Dokument och material
  • Vanliga frågor
  • Sovhygien: övervakning av renheten hos kuddar och sängkläder
  • Nya instrument ger patienter rätt vård - på plats direkt
Logo
Kontakt Stäng
  • Produkter
    • Patientnära diagnostik
      • QuikRead go-systemet
      • QuikRead 101
      • Nova Biomedical
      • SD BIOSENSOR STANDARD F
      • bioLytical Laboratories INSTI®
      • ACRO™ Biotech
      • microINR
      • Certest
      • Actim
      • Hangzhou AllTest Biotech
    • Mikrobiologi
      • Uricult
      • Uricult Vet
      • Cultura M
      • Reagena
      • MIKROGEN serologi
      • Meridian Immunoassays
      • Meridian Curian®
    • Molekylär mikrobiologi
      • Meridian Revogene®
      • Meridian Alethia®
      • MIKROGEN molecular diagnostics
      • SD BIOSENSOR STANDARD M10
    • Hygienkontroll
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / Kollagener
      • UniQ RIA
    • Luftvägsinfektioner
    • Andra
      • Grifols Promonitor®
  • Om oss
    • Aidian i Sverige
    • Styrelse och ledning
    • Hållbarhet
    • Kultur
    • Karriär hos Aidian
  • Nyheter
    • Nyheter
    • Produktnyheter
    • AMR
    • Möten
    • Stories from customers
    • COVID-19
  • Instrument service
    • QuikRead go -serviceorder
    • Vanliga frågor och svar
    • Kontaktinformation
  • Antimikrobiell resistens
    • Om C-reaktivt protein (CRP)
    • CRP och nedre luftvägsinfektioner
    • Material
    • QuikRead go CRP-produkter
    • Spridning av antibiotikaresistenta bakterier
    • Användbara länkar
  • Aidian Academy
    • Allmänt
    • Produktinformation
    • Kurser
    • Dokument och material
    • Vanliga frågor
  • Mässor & utställningar
  • Våra kunder berättar
    • Sovhygien: övervakning av renheten hos kuddar och sängkläder
    • Nya instrument ger patienter rätt vård - på plats direkt
Populära produkter
AllTest hCG snabbtest

AllTest hCG snabbtest

AllTest MONO snabbtest

AllTest MONO snabbtest

Acro Strep A rapid test

Acro Strep A rapid test

Senaste nyheter
Visa alla

Introduktion av QuikRead go Plus Instrument!

20 januari 2025 | Nyheter, Produktnyheter

Increase in influenza and RSV activity in the EU/EEA

14 januari 2025 | Nyheter

Webinar: A Point-of-Care analyzer for DOAC testing

25 november 2024 | Möten

  • Visa alla
  • Inga resultat
  • Loading...
Nyheter

Introduktion av QuikRead go Plus Instrument!

20 januari 2025 | Nyheter, Produktnyheter

Increase in influenza and RSV activity in the EU/EEA

14 januari 2025 | Nyheter

Tillbaka till alla nyheter
23 augusti 2022
Nyheter,
AMR,
COVID-19

COVID-19 pandemic has contributed to the aggravation of Antimicrobial Resistance

Antimicrobial resistance (AMR) is an emerging health threat, but the COVID-19 pandemic set back many actions already combating AMR. Before COVID-19, Antimicrobial stewardship programs and National Actions Plans significantly progressed to slow down Antimicrobial Resistance in many countries. Due to the emergency in the healthcare systems caused by COVID-19, many planned activities were deprioritized and already integrated preventive actions were reversed1,2. For example, antibiotics were prescribed more often without diagnostic confirmation about bacterial infection than before the pandemic1,3.

Recently, the US Centers for Disease Control and Prevention reported that after several years of decrease, antimicrobial resistant hospital-onset infections and deaths increased by at least 15% during the first year of the pandemic. The change in trend indicates that AMR preventive actions must be readdressed and integrated back into the healthcare systems.

Antibiotics were commonly prescribed for hospitalized COVID-19 patients

Antibiotics do not cure viral infections, such as COVID-19, but bacterial co-infections may sometimes accompany viral infections. Treating COVID-19 patients with antibiotics, especially in the early pandemic, seemed to be rather a rule than an exception in many countries. There were concerns about bacterial co-infections, and difficulties in differentiating COVID-19 from community-acquired pneumonia that led excessive antibiotic use. In the USA and China, 80-100% of hospitalized COVID-19 patients received antibiotics1,4. However, bacterial co-infections were reported only on 7-8% of hospitalized and 14% of intensive care patients4, which suggests that antibiotics were often inappropriately used in the treatment of COVID-19.

A person holding a medicine bottle and a pill

The use of broad-spectrum antibiotics increased during COVID-19

In primary care, overall antibiotic consumption decreased in many countries during COVID-19 due to fewer visits to primary care and less spread of respiratory infection. However, the consumption of broad-spectrum antibiotics increased in the EU/EEA countries in both primary care and hospitals.5 Also, in the USA, broad-spectrum antibiotics were commonly used in hospitalized COVID-19 patients1. Broad-spectrum antibiotics are effective against a wide range of bacteria. They are not a first option treatment: they should be used only to treat severe bacterial infections. Therefore, it is necessary to use them correctly to prevent the development of resistance to these drugs.

Immediate actions are needed to optimize antibiotic use and prevent AMR

Now it is more urgent than ever to focus on AMR and reinforce antimicrobial stewardship programs to ensure the appropriate use of antibiotics and other AMR preventive actions in healthcare. Performing fast and accurate point of care tests before antibiotic prescribing, such as QuikRead go CRP and Strep A tests, are an efficient way to optimize antibiotic prescribing and prevent the development of antibiotic resistant bacteria.

Find our portfolio for CRP and Strep A point of care tests from our website: Point of care / QuikRead go


References

  1. Centers of Disease Control and Prevention (CDC). COVID-19: U.S. Impact on Antimicrobial Resistance, Special report 2022. Atlanta, GA: U.S. Department of Health and Human Services. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
  2. Pan American Health Organization. Antimicrobial Resistance, Fueled by the COVID-19 Pandemic. Policy Brief November 2021. https://iris.paho.org/handle/10665.2/55864
  3. Mantzourani et al. To swab or not to swab? Using point-of-care tests to detect Group A Streptococcus infections as part of a Sore Throat Test and Treat service in community pharmacy. J Antimicrobial Chemoter 2021; 77:803–806.
  4. Lansbury et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81(2):266–275.
  5. Organisation for Economic Co-operation and Development (OECD), European Centre for Disease Control and Prevention (ECDC), European Food Safety Authority (EFSA) and European Medicines Agency (EMA). Briefing note: Antimicrobial Resistance in the EU/EEA: A One Health Response. 2022.
Share
Facebook
Twitter
E-post

Aidian Sweden AB

Råsta Strand väg 13C
169 79 Solna


08 623 04 00


Förfrågningar
info@aidian.se


Försäljning
order@aidian.se

Företag
  • Om oss
  • Hållbarhet
  • Karriär hos Aidian
  • Kontakt
Produkter
  • Patientnära diagnostik
  • Mikrobiologi
  • Molekylär mikrobiologi
  • Hygienkontroll
  • RIA / Kollagener
  • Luftvägsinfektioner
  • Andra
Snabblänkar
  • Aidian Academy
  • Aidian Connect
  • Instrument service
Copyright © 2025 Aidian
  • Integritetsskyddspolicy
  • Integritetsmeddelande
  • Cookiepolicy
  • Sociala medier policy